Past performance does not predict future results. Informational only, not investment advice.
BOURLA ALBERT (Chairman & CEO at PFIZER INC) reported an open-market purchase of 38,000 shares of PFE at an average $26.34, roughly $1,000,920, in a Form 4 filed 2026-08-12.
Pfizer at $26 is deeply undervalued at 8.8x forward P/E due to market's fixation on COVID revenue decline and patent cliff. The company is de-risking through the $43B Seagen oncology acquisition, aggressive cost-cutting, and a robust pipeline with 20+ Phase 3 trials in 2026, while offering a protected 6.5% dividend yield and strong upside over 3-5 years.
Pfizer is a deeply undervalued compounder trading at 14.5x P/E despite strategic positioning to exit the COVID downturn. Recent acquisitions (Seagen, obesity) and a government deal de-risk future growth, while the 6.3% dividend provides attractive income on a cheap entry point.
Pfizer trades at a reasonable forward P/E of 18 with a sustainable dividend yield, patent portfolio, and financial capacity to pursue new growth opportunities, making it a solid value holding.
End of results.